Clinical Data BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial Pharmaceutical TechnologyAn indirect comparison highlights the potential of BridgeBio's Attruby to best Pfizer's tafamidis in frontline ATTR-CM.CardiovascularRead full story pharminent May 12, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology An indirect comparison highlights the potential of BridgeBio’s Attruby to best Pfizer’s tafamidis in frontline ATTR-CM. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar)Next: Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
